Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
June 16 2020 - 01:48AM
Business Wire
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY,
NYSE: RDY) today announced that its Annual Report on Form 20-F,
containing its annual consolidated financial statements for the
fiscal year ended 31 March, 2020 was filed with the United States
Securities and Exchange Commission on June 15, 2020.
The Annual Report on Form 20-F is also available on Dr. Reddy’s
website, www.drreddys.com and can be accessed by selecting ‘SEC
filings’ under ‘Reports and Filings’ section under ‘Investors’. ADS
holders may also obtain a hard copy of the Annual Report on Form
20-F at no cost, by sending a written request to the Company’s
registered office or by sending an e-mail to
shares@drreddys.com.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers’, products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2020. The
company assumes no obligation to update any information contained
herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200615005837/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH: +91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com (PH:
+91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2023 to Mar 2024